-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on Vir Biotechnology, Raises Price Target to $21

Benzinga·06/03/2026 14:22:38
Listen to the news
Leerink Partners analyst Roanna Ruiz maintains Vir Biotechnology (NASDAQ:VIR) with a Outperform and raises the price target from $20 to $21.